Tag: ARS Pharmaceuticals

Needless Epinephrine Alternatives

They’re Coming: Needle-Free Emergency Epinephrine Options Currently in Trials

For some, the needle is a barrier to administration but alternatives are on the horizon.
Neffy Intranasal Epinephrine Device

CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...

The market for epinephrine delivery may expand to include non-needle alternatives next year.
Intranasal Spray

Intranasal Epinephrine to Take Center Stage at 2022 AAAAI Annual Meeting

Emergency epinephrine without the jab makes strides.
Intranasal Delivery

Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization

Another company is reporting promising results in the race to bring an intranasal device to market.
Intranasal Spray

Emergency Epinephrine Nasal Spray Takes Final Step Toward Approval in EU

A needle-free option for administration of epinephrine is on the horizon.
Neffy Intranasal Epinephrine Device

ARS Pharmaceuticals Announces New Patent on ARS-1 (Epinephrine Nasal Spray)

Intranasal delivery of emergency epinephrine takes another step closer to becoming a reality.
Intranasal Spray

Study: Intranasal Epinephrine Absorbed Faster Than Injection and Even Better with...

Study compared absorption of epinephrine via nasal spray to that of intramuscular injection.
Nose

ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI...

Neffy™ (formally ARS-1) was fast-tracked by the FDA in 2019 as an intranasal alternative to epinephrine auto-injectors.
Nose

FDA Fast Tracks ARS-1 Intranasal Epinephrine Spray

Company provides a novel means of administering emergency epinephrine.